Reuters reported MRNA more than doubled intraday, with the move intensified by roughly 13.5% short interest in the free float; ORTEX estimated short sellers were facing about $4.8 billion of mark-to-market losses. That means part of today’s price action is a short squeeze—but the underlying catalyst itself is real and unusually material. $Moderna(MRNA.US)


